| Nov 13 |
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 12 |
Adaptimmune Q3 2024 Earnings Preview
|
| Nov 5 |
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
|
| Oct 31 |
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
|
| Oct 10 |
OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR
|
| Sep 25 |
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions
|
| Sep 20 |
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
|
| Sep 16 |
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
|
| Sep 12 |
Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
|
